Feed aggregator

Roche donates additional medicines and diagnostics for Ukraine

World Pharma News - Wed, 03/30/2022 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the donation of additional medicines and diagnostics to Ukraine.

Beyond the already communicated 150,000 packs of an antibiotic medicine the new donation includes another 4,600 packs of specialized medicines for the treatment of influenza, rheumatoid arthritis, SMA and various cancers.

Pfizer and BioNTech receive expanded U.S. emergency use authorization for an additional COVID-19 vaccine booster in individuals aged 50 years and older

World Pharma News - Tue, 03/29/2022 - 10:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use of their COVID-19 vaccine to include a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine.

New nasal spray treats Delta variant infection in mice, indicating broad spectrum results

World Pharma News - Mon, 03/28/2022 - 10:00
Researchers have shown a new compound delivered in a nasal spray is highly effective in preventing and treating COVID-19 caused by the Delta variant in mice.

The researchers, including at UBC, Université de Sherbrooke, and Cornell University, believe this is the first treatment of its kind proven to be effective against all COVID-19 variants of concern reported to date, including alpha, beta, gamma and delta.

Alpaca nanobodies potently neutralize SARS-CoV-2 variants

World Pharma News - Fri, 03/25/2022 - 11:00
Researchers at Karolinska Institutet in Sweden have developed a novel strategy for identifying potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that in cell cultures and mice effectively blocked infection with different SARS-CoV-2 variants.

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

World Pharma News - Thu, 03/24/2022 - 13:00
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

Aspirin may reduce death In hospitalized COVID-19 patients

World Pharma News - Thu, 03/24/2022 - 11:00
Researchers at the George Washington University published findings from the world's largest cohort study showing that hospitalized patients with moderate COVID-19 who were given aspirin early on in their treatment had a lower risk of dying compared to patients who were not given aspirin.

Novel therapeutic strategy shows promise against pancreatic cancer

World Pharma News - Wed, 03/23/2022 - 13:00
Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of mice and vulnerable to immune attack, reducing cancer metastases by 87%. The paper describing the findings published online today in Science Translational Medicine.

Chemical found in leafy greens shown to slow growth of COVID-19 and common cold viruses

World Pharma News - Wed, 03/23/2022 - 11:00
Researchers at Johns Hopkins Children’s Center report evidence from lab experiments that a chemical derived from a compound found abundantly in broccoli and other cruciferous plants may offer a potentially new and potent weapon against the viruses that cause COVID-19 and the common cold. COVID-19 has already killed more than 6 million people worldwide, and studies have shown that common colds cost an estimated economic loss of $25 billion in the U.S. alone each year.

Targeting a human protein may stop Ebola virus in its tracks

World Pharma News - Tue, 03/22/2022 - 13:00
To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase.

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Pfizer to supply UNICEF up to 4 million treatment courses of novel COVID-19 oral treatment for low- and middle-income countries

World Pharma News - Tue, 03/22/2022 - 11:00
Pfizer Inc. (NYSE: PFE) announced today an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval.

COVID-19 Increases risk of type 2 diabetes

World Pharma News - Mon, 03/21/2022 - 13:00
People who have had COVID-19 are at increased risk of developing type 2 diabetes. This is the result of a study by DDZ, DZD and IQVIA, which has now been published in Diabetologia.

Studies show that the human pancreas can also be a target of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2 virus).

Scientists discover how molecule becomes anticancer weapon

World Pharma News - Mon, 03/21/2022 - 11:00
Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule.

The anti-cancer molecule salinosporamide A, also called Marizomb, is in Phase III clinical trials to treat glioblastoma, a brain cancer. Scientists now for the first time understand the enzyme-driven process that activates the molecule.

Key antiviral treatment for COVID-19 still effective despite resistance fears

World Pharma News - Fri, 03/18/2022 - 13:00
An antiviral drug used to treat SARS-CoV-2 remains effective against the newest variants of the evolving virus, according to Rutgers researchers.

The study, published in the journal Cell Research, is one of the first to explore the full extent of SARS-CoV-2 mutations.

Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates

World Pharma News - Fri, 03/18/2022 - 11:00
Sanofi and Seagen Inc. (Nasdaq:SGEN) announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology.

Engineering an "invisible cloak" for bacteria to deliver drugs to tumors

World Pharma News - Thu, 03/17/2022 - 13:00
Columbia Engineering researchers report that they have developed a "cloaking" system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells in mice. By manipulating the microbes’ DNA, they programmed gene circuits that control the bacteria surface, building a molecular "cloak" that encapsulates the bacteria.

Pfizer and BioNTech aubmit for U.S. Emergency Use Authorization of an additional booster dose of their COVID-19 vaccine for older adults

World Pharma News - Thu, 03/17/2022 - 11:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose for adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.

Programming the immune system to supercharge cancer cell therapies

World Pharma News - Wed, 03/16/2022 - 13:00
The first FDA-approved gene therapies are living drugs: immune cells taken from cancer patients engineered to target tumor cells. However, for many patients, these advanced therapies do not result in a long-lasting remission. Now, scientists at the New York Genome Center and New York University have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumor cells.

A possible new COVID-19 vaccine could be accessible for more of the world

World Pharma News - Wed, 03/16/2022 - 11:00
While many people in wealthier countries have been vaccinated against COVID-19, there is still a need for vaccination in much of the world. A new vaccine developed at MIT and Beth Israel Deaconess Medical Center may aid in those efforts, offering an inexpensive, easy-to-store, and effective alternative to RNA vaccines.

FDA approves first generic of Symbicort to treat asthma and COPD

World Pharma News - Tue, 03/15/2022 - 13:00
Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Spider silk can stabilize cancer-suppressing protein

World Pharma News - Tue, 03/15/2022 - 11:00
The p53 protein protects our cells from cancer and is an interesting target for cancer treatments. The problem is, however, that it breaks down rapidly in the cell. Researchers at Karolinska Institutet in Sweden have now found an unusual way of stabilising the protein and making it more potent. By adding a spider silk protein to p53, they show that it is possible to create a protein that is more stable and capable of killing cancer cells.